Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• The proteasome is essential for maintaining intracellular protein homeostasis by degrading misfolded or damaged proteins.
• Proteasome inhibition is a validated anti-cancer therapy, with approved drugs for multiple myeloma.
• Emerging research highlights the therapeutic potential of proteasome modulation in non-cancerous diseases.

Purpose of the Study:

• To review recent advancements in proteasome inhibitors for diverse diseases.
• To summarize structure-activity relationships of these inhibitors.
• To explore the expanding therapeutic landscape of proteasome inhibition.

Main Methods:

• Literature review of recent studies on proteasome inhibitors.
• Analysis of structure-activity relationships.
• Synthesis of findings across various disease areas.

Main Results:

• Proteasome inhibitors demonstrate therapeutic efficacy in preclinical and clinical studies for various conditions.
• Significant progress has been made in understanding the structure-activity relationships, guiding inhibitor design.
• The application of proteasome inhibitors is expanding beyond oncology.

Conclusions:

• Proteasome inhibition offers a promising therapeutic strategy for a wide range of diseases, including infectious, neurodegenerative, and autoimmune disorders.
• Further research into structure-activity relationships will facilitate the development of more targeted and effective proteasome inhibitors.
• The proteasome represents a versatile therapeutic target with broad clinical implications.